Form 4: Lexeo Therapeutics Executive Acquires and Disposes of Shares in Recent Transaction

Jenny Robertson, Chief Legal & Admin Officer of Lexeo Therapeutics, reports acquiring and disposing of common stock and stock options in a transaction dated January 7, 2025.

Summary

• On January 7, 2025, Jenny Robertson, the Chief Legal & Admin Officer of Lexeo Therapeutics, engaged in transactions involving the company's securities.
• Robertson acquired 36,250 shares of common stock in the form of restricted stock units (RSUs).
• These RSUs vest over time, with 25% vesting on February 15, 2026, and the remainder vesting quarterly thereafter, contingent upon continued service.
• Robertson also disposed of 60,000 shares of common stock.
• Additionally, Robertson acquired options to purchase 72,500 shares of common stock at an exercise price of $7.33.
• These options vest over time, with 25% vesting on January 7, 2026, and the remainder vesting monthly thereafter, contingent upon continued service.
• Following these transactions, Robertson directly owns 72,500 derivative securities.

Sentiment

Score: 5

Explanation: This is a routine disclosure of insider transactions. The sentiment is neutral as it doesn't inherently indicate positive or negative performance for the company.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor management's alignment with shareholder interests.

Stakeholder Impact

• Shareholders can monitor insider transactions to gain insights into management's perspective on the company's stock.

Key Dates